J Clin Pharmacol. 2005 Oct;45(10):1172-8.

Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects.

Jermany J, Branson J, Schmouder R, Guillaume M, Rordorf C.

Source

Exploratory Clinical Development, Novartis Pharma AG, WSJ-103-4 D, CH-4002 Basel, Switzerland.

Abstract

This randomized, double-blind, placebo-controlled study evaluated the pharmacodynamic effects of concomitant low-dose aspirin and lumiracoxib in healthy subjects. Participants received lumiracoxib 400 mg once daily (n = 14) or placebo (n = 14) for 11 days, with concomitant low-dose aspirin (75 mg once daily) from days 5 to 11. Ex vivo pharmacodynamic assessments included assays of platelet aggregation and urinary thromboxane and prostacyclin metabolite profile. Arachidonic acid-stimulated platelet aggregation was reduced from 76.3% on day 4 to 4.8% on day 11 in the placebo group and from 75.8% on day 4 to 5.1% on day 11 in the lumiracoxib group. Collagen-induced platelet aggregation was reduced from 77.5% on day 4 to 52.8% on day 11 in the placebo group and from 79.5% on day 4 to 55.9% on day 11 in the lumiracoxib group. Urinary thromboxane and prostacyclin were unaffected by lumiracoxib. In conclusion, concomitant lumiracoxib did not interfere with the cyclooxygenase-1-mediated antiplatelet effects of low-dose aspirin.

PMID:: 16172182; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Medical

Blood Thinners - MedlinePlus Health Information

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. [J Clin Pharmacol. 2000]
A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
Greenberg HE, Gottesdiener K, Huntington M, Wong P, Larson P, Wildonger L, Gillen L, Dorval E, Waldman SA. J Clin Pharmacol. 2000 Dec; 40(12 Pt 2):1509-15.
Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. [J Clin Pharmacol. 2002]
Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers.
Wilner KD, Rushing M, Walden C, Adler R, Eskra J, Noveck R, Vargas R. J Clin Pharmacol. 2002 Sep; 42(9):1027-30.
Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. [Circulation. 2007]
Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US. Circulation. 2007 Jun 26; 115(25):3156-64. Epub 2007 Jun 11.
Review Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. [J Am Coll Cardiol. 2005]
Review Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects.
Capone ML, Sciulli MG, Tacconelli S, Grana M, Ricciotti E, Renda G, Di Gregorio P, Merciaro G, Patrignani P. J Am Coll Cardiol. 2005 Apr 19; 45(8):1295-301.
Review Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. [Clin Pharmacokinet. 2005]
Review Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor.
Rordorf CM, Choi L, Marshall P, Mangold JB. Clin Pharmacokinet. 2005; 44(12):1247-66.

See reviews... See all...

Cited by 2 PubMed Central articles

COX-2 Inhibition by Use of Rofecoxib or High Dose Aspirin Enhances ADP-Induced Platelet Aggregation in Fresh Blood. [Open Cardiovasc Med J. 2010]
COX-2 Inhibition by Use of Rofecoxib or High Dose Aspirin Enhances ADP-Induced Platelet Aggregation in Fresh Blood.
Borgdorff P, Handoko ML, Wong YY, Tangelder GJ. Open Cardiovasc Med J. 2010 Oct 21; 4:198-205. Epub 2010 Oct 21.
Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis. [Core Evid. 2007]
Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis.
Profit L, Chrisp P. Core Evid. 2007 Nov 30; 2(2):131-50. Epub 2007 Nov 30.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low...
Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects.
J Clin Pharmacol. 2005 Oct ;45(10):1172-8.

PubMed
Cell lineage in molluscan development.
Cell lineage in molluscan development.
Microsc Res Tech. 1992 Jun 15 ;22(1):75-102.

PubMed
Substrate specificity of protein kinases and computational prediction of substra...
Substrate specificity of protein kinases and computational prediction of substrates.
Biochim Biophys Acta. 2005 Dec 30 ;1754(1-2):200-9. Epub 2005 Sep 9 .

PubMed
Genetic diversity and kinetic properties of Trypanosoma cruzi dihydroorotate deh...
Genetic diversity and kinetic properties of Trypanosoma cruzi dihydroorotate dehydrogenase isoforms.
Parasitol Int. 2006 Mar ;55(1):11-6. Epub 2005 Sep 19 .

PubMed
Two C4-dicarboxylate transport systems in Rhizobium sp. NGR234: rhizobial dicarb...
Two C4-dicarboxylate transport systems in Rhizobium sp. NGR234: rhizobial dicarboxylate transport is essential for nitrogen fixation in tropical legume symbioses.
Mol Plant Microbe Interact. 1992 Mar-Apr ;5(2):179-86.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Cited by 2 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information